Beijing QMLC Stem Cell Technology Co., Ltd, founded in March, 2009, is located at Beijing Tsinghua Science Park. QMLC is a high-tech company engaged in research and development of clinical applications of stem cells, stem cell bank and related products. The whole production chain includes upstream—construction and management of stem cell bank; middle stream—research, development and selling of regional and international products; downstream—clinical applications, which translate lab research into clinic and manufacturing.

 

After development within several years, QMLC has made significant progress:

 

 

The basic technology comes from University of Illinois, University of Wisconsin, Tsinghua University, Chinese Academy of Medicine and Peking University. The Stem Cell Research & Development Center of QMLC has been joined with the international talents including 6 Ph.D. scientists and 12 researchers with M.S degree. Our products include 3 stem cell kits that can be used for cell preparation by clinical and research institutions. Since we have a world-class R&D team, the best one in China, we are in better position in competition in stem cell product market, ensuring long-term development.

 

 

The novel system developed by QMLC for stem cell preparation employing cell culturing medium with factors from plant, induction factors, as well as using 3D culturing technology. The state-of-the-art technologies are unique, effective and safe in accordance with the standards, and have advantages in market competition.

 

 

QMLC currently is able to prepare 61 kinds of cells for clinical application by using technology developed in the company. It is No.1 in China in terms of number of cell species for treatment of all kind of diseases.

 

 

Our 3D cell culturing technology can significantly improve the culturing efficiency and the activity of cell preparations with reduced toxicity. We have our own IPR for this technology.

 

 

QMLC is the only stem cell company using cell medium with factors from plant for cell culturing, which can improve the cell activity, and decrease the probability of mutagenesis.

 

 

QMLC is the company which applied patents in stem cell technology more than any other companies in China. Among the patents applied, there are 4 US patents, 32 Chinese invention patents and 1 Chinese patent of utility model, and all of them are used in AAA hospitals in China. QMLC has published a number of research papers and joined the national 863 Research Project, and had several new findings in basic and clinical research regarding to stem cells.

 

 

QMLC is the only company obtained the certificates from both CQC and IQNET. The quality control system ensures that QMLC products have better safety and higher quality.

 

QMLC always carry out high quality control. After establishment of enterprise SOP preparation procedures, our products have passed 13 inspections conducted by national inspection laboratory.

 

 

QMLC is the first company passed the inspection by National Construction Quality Control Center to be the GMP standard laboratory. The excellent environment for cell preparation ensures high quality of the cells with minimum contamination.

 

QMLC is on its way to be the No.1 in industrialization in next few years based on research and development, to make significant contributions for human health.